King's College London

Application of synthetic medicinal chemistry and chemical biology techniques to the design, synthesis and evaluation of novel anticancer and antibacterial agents. 

Current Projects

• Antibiotic Resistance Breaker (ARB) technology.

• Development of new classes of antibacterial agents against multidrug-resistant pathogens.

• Development of new generation antifungal agents.

• Development of chemoresistance breakers against cancer stem cells.

• Development of Anticancer Agents (DNA Interactive and PROTAC).

• Development of chemical tools (e.g., EPI, membrane probes, enzyme inhibitors etc.) to study antimicrobial resistance.

• Development of orthosteric biased antagonists to P2Y1 for anti-inflammatory therapy.

• The exploitation of anaplerotic node as a therapeutic target against Mycobacterium tuberculosis.

• Development of new antibiofilm agents through repurposing of existing licensed drugs.

• Identification of New Therapeutic Combinations for Clinical Trial against COVID-19 Through Repurposing of Drugs with Known Safety Profile.

• Development of a Gram-negative membrane penetration rule.

• Mechanistic evaluation of natural products from plant origin.